Page 21 - Policy Wording - Commercial Underwriting Mandates & Guidelines Binder Addendum

Annexure A – Treaty Exclusions
#
Company Name
Headquarter location
29 GLAXOSMITHKLINE
30 GRIFOLS (including former Talecris Biotherapeutics)
31 HOSPIRA
32 IPSEN (Beaufour Ipsen)
33 JOHNSON & JOHNSON (including former Synthes)
34 KCI LifeCell
35 KYOWA HAKKO KIRIN
36 LABORATOIRE SERVIER
37 LILLY (ELI)
38 LUNDBECK
39 MALLINCKRODT
40 MEDTRONIC
41 MERCK & CO (including former Schering-Plough)
42 MERCK KGAA (including former Serono)
43 MITSUBISHI TANABE PHARMA (including former Tanabe)
44 MYLAN
45 NOVARTIS (including former Chiron)
46 NOVO NORDISK
47 OTSUKA PHARMACEUTICAL
48 PAR PHARMACEUTICAL
49 PERRIGO
50 PFIZER (including former King Pharmaceuticals and Wyeth)
51 PROCTER & GAMBLE
52 PURDUE FREDERICK/PRA Holding/PURDUE PHARMA LP
53 RANBAXY LABORATORIES
54 ROCHE (including former Genentech)
55 SANOFI (including former Genzyme)
56 SHIONOGI
57 SHIRE
58 SMITH & NEPHEW
59 ST. JUDE MEDICAL
60 STRYKER
61 TAKEDA (including former TAP Pharmaceutical Products)
62 TEVA PHARMACEUTICAL (including former Ivax Corp., Barr Pharmaceuticals and Cephalon)
63 UCB (including former Schwarz Pharma)
64 VALEANT PHARMACEUTICALS INTERNATIONAL vi
65 ViiV HEALTHCARE
66 ZIMMER
4.11.1 4.11.2
UK SPAIN USA France USA USA Japan France USA Denmark Ireland USA USA Germany Japan USA Switzerland Denmark Japan USA Ireland USA USA USA India Switzerland France Japan UK
UK USA USA Japan Israel
Belgium Canada UK USA
On January 1, 2013, AbbVie became an independent company (separation from Abbott).
Actavis: Watson Pharmaceuticals completed its acquisition of Actavis in November 2012. In January 2013 the company announced that it has adopted the name Actavis Inc. as its new global name.
Commercial Underwriting Mandates & Guidelines – Binder Addendums – Version 2 2020 18